Contrasting Promis Neurosciences (NASDAQ:PMN) and Bavarian Nordic (OTCMKTS:BVNRY)

Bavarian Nordic (OTCMKTS:BVNRY) and Promis Neurosciences (NASDAQ:PMN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Bavarian Nordic and Promis Neurosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bavarian Nordic	0	0	0	0	0.00
Promis Neurosciences	1	0	2	1	2.75

Promis Neurosciences has a consensus target price of $26.50, suggesting a potential upside of 174.61%. Given Promis Neurosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Promis Neurosciences is more favorable than Bavarian Nordic.

Valuation & Earnings

This table compares Bavarian Nordic and Promis Neurosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bavarian Nordic	$945.43 million	2.33	$208.23 million	$0.76	12.21
Promis Neurosciences	N/A	N/A	-$39.72 million	($14.51)	-0.67

Bavarian Nordic has higher revenue and earnings than Promis Neurosciences. Promis Neurosciences is trading at a lower price-to-earnings ratio than Bavarian Nordic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bavarian Nordic and Promis Neurosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bavarian Nordic	19.74%	9.37%	8.10%
Promis Neurosciences	N/A	-237.99%	-151.04%

Volatility and Risk

Bavarian Nordic has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500.

Insider & Institutional Ownership

50.1% of Promis Neurosciences shares are held by institutional investors. 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Bavarian Nordic beats Promis Neurosciences on 8 of the 14 factors compared between the two stocks.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

About Promis Neurosciences

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.